PE20080688A1 - Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de trpv1 y su preparacion - Google Patents
Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de trpv1 y su preparacionInfo
- Publication number
- PE20080688A1 PE20080688A1 PE2007000976A PE2007000976A PE20080688A1 PE 20080688 A1 PE20080688 A1 PE 20080688A1 PE 2007000976 A PE2007000976 A PE 2007000976A PE 2007000976 A PE2007000976 A PE 2007000976A PE 20080688 A1 PE20080688 A1 PE 20080688A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- indol
- optionally substituted
- trpv1
- antagonists
- Prior art date
Links
- 102000003566 TRPV1 Human genes 0.000 title abstract 2
- 101150016206 Trpv1 gene Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
REFERIDA A UN DERIVADO DE INDOL DE FORMULA (I), DONDE X1 ES H, HALOGENO, ALQUILO C1-C6, CICLOALQUILO C3-C7, ENTRE OTROS; X2 ES H, CN, ALQUILO C1-C6, ENTRE OTROS; X3 Y X4 SON H, ALQUILO C1-C3, ALCOXILO C1-C6, CN, ENTRE OTROS; Z1, Z2, Z3 Y Z4 SON NITROGENO, CR6, ENTRE OTROS; n ES UN ENTERO DE ENTRE 0 Y 3; Y ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDOS CON HALOGENO, ALQUILO C1-C6, OH, ENTRE OTROS; Z ES UNA AMINA CICLICA CONFORMADA POR N, A, B Y L, DONDE A ES UN ALQUILENO C1-C7 OPCIONALMENTE SUSTITUIDO CON R8, B ES UN ALQUILENO OPCIONALMENTE SUSTITUIDO CON R9, L ES UN ENLACE, O, S O N, DONDE N ES OPCIONALMENTE SUSTITUIDO CON R10 O R11; R6 ES H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; R8, R9 Y R10 SON TAL QUE DOS GRUPOS R8 O DOS GRUPOS R9 PUEDEN FORMAR UN ENLACE O UN GRUPO ALQUILENO C1-C6, R9 Y R10 PUEDEN FORMAR UN ENLACE O UN GRUPO ALQUILENO C1-C6; R11 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C7, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-{6-[((R)-3-TERC-BUTOXICARBONILAMINO)-PIRROLIDIN-1-IL]-PIRIDIN-3-IL}-5-FLUORO-1-(3-FLUOROBENCIL)-1H-INDOL-2-CARBOXAMIDA, N-[6-(PIRROLIDIN-1-IL]-PIRIDIN-3-IL}-5-FLUORO-1-(3-FLUOROBENCIL)-1H-INDOL-2-CARBOXAMIDA, N-{6-[(R)-3-AMINOPIRROLIDIN-1-IL]-5-FLUORO-1-(3-FLUOROBENCIL)-1H-INDOL-2-CARBOXAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES TRPV1 (VR1) Y SON UTILES EN EL TRATAMIENTO DEL DOLOR, INFLAMACION, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0606988A FR2904316B1 (fr) | 2006-07-31 | 2006-07-31 | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080688A1 true PE20080688A1 (es) | 2008-07-24 |
Family
ID=37806631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000976A PE20080688A1 (es) | 2006-07-31 | 2007-07-26 | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de trpv1 y su preparacion |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US7786104B2 (es) |
| EP (1) | EP2049525B1 (es) |
| JP (1) | JP5306201B2 (es) |
| KR (1) | KR20090033885A (es) |
| CN (1) | CN101511819B (es) |
| AR (1) | AR062143A1 (es) |
| AT (1) | ATE453637T1 (es) |
| AU (1) | AU2007280326B2 (es) |
| BR (1) | BRPI0715199A2 (es) |
| CA (1) | CA2658799C (es) |
| CL (1) | CL2007002169A1 (es) |
| CO (1) | CO6150179A2 (es) |
| CY (1) | CY1109944T1 (es) |
| DE (1) | DE602007004119D1 (es) |
| DK (1) | DK2049525T3 (es) |
| EA (1) | EA017375B1 (es) |
| ES (1) | ES2338610T3 (es) |
| FR (1) | FR2904316B1 (es) |
| HR (1) | HRP20100121T1 (es) |
| IL (1) | IL196571A0 (es) |
| JO (1) | JO2644B1 (es) |
| MA (1) | MA30695B1 (es) |
| ME (1) | ME00590A (es) |
| MX (1) | MX2009001222A (es) |
| MY (1) | MY145031A (es) |
| NO (1) | NO20090952L (es) |
| NZ (1) | NZ574345A (es) |
| PE (1) | PE20080688A1 (es) |
| PL (1) | PL2049525T3 (es) |
| PT (1) | PT2049525E (es) |
| RS (1) | RS51235B (es) |
| SI (1) | SI2049525T1 (es) |
| TW (1) | TW200813023A (es) |
| UY (1) | UY30518A1 (es) |
| WO (1) | WO2008015335A1 (es) |
| ZA (1) | ZA200900505B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| FR2926554B1 (fr) * | 2008-01-22 | 2010-03-12 | Sanofi Aventis | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
| FR2926553B1 (fr) * | 2008-01-23 | 2010-02-19 | Sanofi Aventis | Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique |
| CA2756870A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
| CA2857344C (en) | 2011-12-21 | 2019-02-12 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| SG11201501362PA (en) | 2012-08-28 | 2015-03-30 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| CA2899706C (en) | 2013-02-28 | 2021-10-19 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| WO2014161888A1 (en) | 2013-04-03 | 2014-10-09 | Janssen R&D Ireland | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| WO2014184365A1 (en) | 2013-05-17 | 2014-11-20 | Janssen R&D Ireland | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| EP3357906B1 (en) | 2013-07-25 | 2019-12-04 | Janssen Sciences Ireland Unlimited Company | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| US9567299B2 (en) | 2013-10-23 | 2017-02-14 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| AU2015214096B2 (en) | 2014-02-05 | 2021-02-11 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
| DK3102572T3 (en) | 2014-02-06 | 2019-02-04 | Janssen Sciences Ireland Uc | SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B |
| WO2016149581A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10077239B2 (en) | 2015-09-29 | 2018-09-18 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
| KR20180129943A (ko) | 2016-04-15 | 2018-12-05 | 노비라 테라퓨틱스, 인코포레이티드 | 캡시드 조립 억제제를 포함하는 배합물 및 방법 |
| WO2017210545A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| UA123810C2 (uk) | 2017-01-23 | 2021-06-02 | Цадент Терапеутікс, Інк. | Модулятори калієвих каналів |
| MA52019A (fr) | 2018-03-14 | 2021-01-20 | Janssen Sciences Ireland Unlimited Co | Schéma posologique de modulateur d'assemblage de capside |
| KR20210080446A (ko) | 2018-10-22 | 2021-06-30 | 카덴트 테라퓨틱스, 인크. | 칼륨 채널 조절제의 결정 형태 |
| TW202045499A (zh) | 2019-02-22 | 2020-12-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用於治療ｈｂｖ感染或ｈｂｖ誘發疾病之醯胺衍生物 |
| AU2020269897A1 (en) | 2019-05-06 | 2021-10-14 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL248308A (es) | 1958-09-30 | |||
| US4104385A (en) | 1976-08-19 | 1978-08-01 | Sterling Drug Inc. | Cyclic alkylidenyl N-[6-(amino)-3-pyridazinyl]aminomethylenemalonates |
| DE60115092T2 (de) | 2000-12-12 | 2006-03-30 | Neurogen Corp., Brandford | Spiro[isobenzofuran-1,4'-piperidin]-3-one und 3h-spiroisobenzofuran-1,4'-piperidine |
| FR2832148B1 (fr) * | 2001-11-14 | 2004-05-21 | Oreal | Nouvelles bases d'oxydation 2,5-diaminopyridine utiles pour la teinture des fibres keratiniques |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| US20070066640A1 (en) | 2003-01-16 | 2007-03-22 | Emiliano Castiglioni | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists |
| US7223788B2 (en) * | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| GB0314136D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0322016D0 (en) | 2003-09-19 | 2003-10-22 | Merck Sharp & Dohme | New compounds |
| EP1673355A1 (en) | 2003-09-22 | 2006-06-28 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| WO2005035526A1 (en) | 2003-10-09 | 2005-04-21 | Argenta Discovery Ltd. | Bicyclic compounds and their therapeutic use |
| GB0326633D0 (en) * | 2003-11-14 | 2003-12-17 | Merck Sharp & Dohme | Therapeutic agents |
| EP1802603A1 (en) | 2004-10-12 | 2007-07-04 | AstraZeneca AB | Quinoline derivatives |
| US7875627B2 (en) * | 2004-12-07 | 2011-01-25 | Abbott Laboratories | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof |
| FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| JP2009501217A (ja) | 2005-07-15 | 2009-01-15 | アストラゼネカ アクチボラグ | 治療薬 |
| JP5076091B2 (ja) * | 2005-11-28 | 2012-11-21 | マドリガル・ファーマシューティカルズ・インコーポレーテッド | ジアシルグリセロールアシルトランスフェラーゼ（ｄｇａｔ）のインヒビター |
-
2006
- 2006-07-31 FR FR0606988A patent/FR2904316B1/fr not_active Expired - Fee Related
-
2007
- 2007-07-20 TW TW096126658A patent/TW200813023A/zh unknown
- 2007-07-24 CL CL200702169A patent/CL2007002169A1/es unknown
- 2007-07-26 PE PE2007000976A patent/PE20080688A1/es not_active Application Discontinuation
- 2007-07-30 DK DK07823371.5T patent/DK2049525T3/da active
- 2007-07-30 MY MYPI20090381A patent/MY145031A/en unknown
- 2007-07-30 ZA ZA200900505A patent/ZA200900505B/xx unknown
- 2007-07-30 JP JP2009522302A patent/JP5306201B2/ja not_active Expired - Fee Related
- 2007-07-30 CN CN200780032445.6A patent/CN101511819B/zh not_active Expired - Fee Related
- 2007-07-30 PT PT07823371T patent/PT2049525E/pt unknown
- 2007-07-30 AT AT07823371T patent/ATE453637T1/de active
- 2007-07-30 KR KR1020097002074A patent/KR20090033885A/ko not_active Application Discontinuation
- 2007-07-30 PL PL07823371T patent/PL2049525T3/pl unknown
- 2007-07-30 AR ARP070103358A patent/AR062143A1/es not_active Application Discontinuation
- 2007-07-30 BR BRPI0715199-3A2A patent/BRPI0715199A2/pt not_active IP Right Cessation
- 2007-07-30 ME MEP-30/09A patent/ME00590A/xx unknown
- 2007-07-30 CA CA2658799A patent/CA2658799C/fr active Active
- 2007-07-30 MX MX2009001222A patent/MX2009001222A/es active IP Right Grant
- 2007-07-30 AU AU2007280326A patent/AU2007280326B2/en not_active Ceased
- 2007-07-30 JO JO2007310A patent/JO2644B1/en active
- 2007-07-30 SI SI200730186T patent/SI2049525T1/sl unknown
- 2007-07-30 WO PCT/FR2007/001316 patent/WO2008015335A1/fr active Application Filing
- 2007-07-30 NZ NZ574345A patent/NZ574345A/en not_active IP Right Cessation
- 2007-07-30 DE DE602007004119T patent/DE602007004119D1/de active Active
- 2007-07-30 EA EA200970171A patent/EA017375B1/ru not_active IP Right Cessation
- 2007-07-30 RS RSP-2010/0139A patent/RS51235B/sr unknown
- 2007-07-30 ES ES07823371T patent/ES2338610T3/es active Active
- 2007-07-30 EP EP07823371A patent/EP2049525B1/fr active Active
- 2007-07-31 UY UY30518A patent/UY30518A1/es not_active Application Discontinuation
-
2009
- 2009-01-18 IL IL196571A patent/IL196571A0/en unknown
- 2009-01-26 US US12/359,468 patent/US7786104B2/en not_active Expired - Fee Related
- 2009-01-29 CO CO09008274A patent/CO6150179A2/es unknown
- 2009-02-13 MA MA31642A patent/MA30695B1/fr unknown
- 2009-03-02 NO NO20090952A patent/NO20090952L/no not_active Application Discontinuation
-
2010
- 2010-03-04 HR HR20100121T patent/HRP20100121T1/hr unknown
- 2010-03-22 CY CY20101100268T patent/CY1109944T1/el unknown
- 2010-07-19 US US12/838,771 patent/US8586573B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080688A1 (es) | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de trpv1 y su preparacion | |
| PE20081549A1 (es) | Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamida y su preparacion | |
| PA8580301A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| AR013184A1 (es) | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis | |
| PE20121091A1 (es) | Derivados de purina o deazapurina utiles en el tratamiento de (inter alia) infecciones virales | |
| AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
| AR016762A1 (es) | Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo | |
| PE20090556A1 (es) | DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO [1,2-b]-PIRIDAZINA COMO INHIBIDORES DE CASEINA QUINASAS Y SU PREPARACION | |
| UY28135A1 (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal | |
| PE20060737A1 (es) | 3-AMINO-PIRAZOL[3,4b] PIRIDINAS COMO INHIBIDORES DE PROTEINTIROSINQUINASAS Y SU PREPARACION | |
| PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
| PE20181491A1 (es) | Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| DK1697371T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| DK1697370T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| PE20091307A1 (es) | Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparacion y su aplicacion en terapeutica | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| PE20091561A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
| UY29246A1 (es) | Nuevos compuestos | |
| UY32483A (es) | Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio | |
| UY27503A1 (es) | Nuevos derivados de piperazina | |
| DE602005016261D1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| AR061973A1 (es) | Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos | |
| PE20130191A1 (es) | Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |